Investor Relations Activity Category

□Specific Object Research □Analyst Meeting

□ Media interviews □Performance briefing

□ press conference □Roadshow activities

□ field trip

√other （Chongqing District Collective Reception Day Event

Names of participating units and personnel

Investors' online questions

time

2024year11the moon28sun (Thursday) afternoon 15:00~17:05

location

The company uses panoramic network“Investor Relations Interactive Platform”（https://ir.p5w.net）Adopting a remote network approachParticipate in the collective reception day for investors of listed companies in Chongqing.

Name of receptionist of listed company

1Secretary Tang Qin

2Financial Director Yu Xuesong

Introduction to the main content of investor relations activities

Questions raised by investors and responses from the company

The company has responded to the questions raised by investors during this briefing:

1The market value of the company has not changed for so many years. Do you think so?

Market value changes are influenced by various factors. The company will do a good job in business management, actively return to shareholders, enhance company value through multiple channels, manage investor relations well, and continuously strengthen market value management. Thank you!

2What are the company's specialty drugs?

The company's specialty drugs mainly include Doxophylline, Neoergoline, Sulindac Tablets, Glutathione and other products. Thank you!

3What is the expected production capacity of the company's high-end production site construction project for green and intelligent raw materials?

Expected production capacity173ton/Year, thank you

4Given that some executives and senior executives hold a significant number of restricted shares, may this affect their decision-making and commitment to the long-term development of the company?Does the company have any special management mechanisms or policies to balance this potential conflict of interest?

The shareholding of company executives is locked in proportion according to relevant regulations. Thank you!

5Note that the company's long-term borrowings in the third quarter have significantly increased compared to last year. Does this mean that the company is making some major investments or expansion plans?If so, could you please disclose the specific direction and expected impact?

Long term borrowings of the company at the end of the third quarter1.89Billion, decreased from the beginning of the year, thank you for your attention!

6Company leaders still have strategic vision! Worth affirming!

Thank you for your affirmation!

7What are the plans or progress in the development of innovative drugs? Are there any new drugs that are convenient to mention?

The company will disclose the progress of drug research and development that has entered the registration process in its regular reports. Thank you!

8May I ask if the company's stock price will remain stable for the long term10Below yuan, does such a low stock price mean that the company's products do not have a competitive advantage? Or is it that the top management of the company doesn't really care about their company's stock price or the interests of investors?

The stock price not only reflects the fundamentals, but is also influenced by market factors. The company's management attaches great importance to the interests of investors, actively completes the fundamentals, and returns to investors. Thank you

9What is the expected construction period for the high-end API production base project?

The construction period of Bosheng Pharmaceutical is about two years, and the actual construction progress shall prevail. Thank you!

10What are the company's plans for future development, such as how to grow and strengthen

The company focuses on generic drugs, fully leverages the advantages of a complete industry chain, actively participates in market competition, and improves performance returns for investors. Thank you!

11What are the research and development progress in anti-tumor drugs?

The drugs currently in the registration process of the company will be summarized and disclosed in the annual and semi annual reports. Any progress made will be promptly disclosed. Thank you!

12What phase of clinical trials is Yunuojin growth hormone currently in? Please answer the issue directly without being vague.

Yunuojin growth hormone is currently in phase III clinical stage.

13Secretary of the Board, is the reason why the company does not repurchase or cancel shares because the company has no value? I still prefer to use the money for reckless investment and provision for goodwill rather than distribute it to shareholders. Please answer directly.

If the company has a plan to repurchase shares, it will disclose information through designated media. The company has distributed cash dividends in accordance with the conditions over the years, and will continue to actively repay investors. Thank you!

14Over the years, has the company ever engaged in market value management? Protect the rights and interests of shareholders.

Hello, thank you for your question. The company will strive to do a good job in production and operation, actively repay investors, manage investor relations, and legally and compliantly manage market value. Thank you!

15How does the company view and evaluate the future competitive situation in the current market environment?Are there any new market entry points or product line development plans to ensure the company's sustained growth and withstand potential market competition pressures?！

As a chemical pharmaceutical enterprise, the company is currently facing a fierce market competition environment. Against the backdrop of industry policy changes and market environment changes, the company may face increasingly fierce market competition. The company will continue to promote product research and development, optimize product structure, enrich product types, continuously improve risk resistance capabilities, and strive to maintain stable performance in market competition. Thank you!

16Long term stock price downturn, may I ask the chairman of the company, does your company not know about market value management? Are there any measures in place? For example, repurchase and cancellation, or merger and reorganization.

The company currently has no plans for equity repurchase or restructuring. If there are any related plans, we will disclose them according to regulations. Thank you for your attention!

17Given that the third quarter report has not been audited, investors are concerned about the accuracy and reliability of the data. Does the company have plans to introduce external auditing in future reports to improve the transparency and credibility of financial information?

Thank you for your question. The company's annual reports have been audited by external auditing agencies over the years, and the data disclosed in the company's regular reports is true and accurate. In the future, the company will continue to strengthen its internal audit work, cooperate with external auditing agencies to conduct annual report audits, and continuously improve the accuracy of financial information. Thank you!

Attachment List (if any)

not have

date

2024-11-28